Vivos Therapeutics (VVOS) Debt to Equity (2019 - 2026)
Vivos Therapeutics (VVOS) reported Debt to Equity of -$6.78 for Q1 2026, down 19.14% on a QoQ basis from -$5.69 in Q4 2025.
Vivos Therapeutics (VVOS) has 5 years of Debt to Equity data on file, last reported at -$6.78 in Q1 2026.
- Quarterly Debt to Equity changed N/A year-over-year to -$6.78 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$6.78 (changed N/A YoY) and the FY2025 annual result came in at -$5.69, changed N/A from the prior year.
- Debt to Equity eased to -$6.78 in Q1 2026 per VVOS's latest filing, from -$5.69 in the prior quarter.
- Across five years, Debt to Equity topped out at $3.44 in Q3 2025 and bottomed at -$6.78 in Q1 2026.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Debt/Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn | 0.65 |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn | 0.64 |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn | 0.57 |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn | 0.42 |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn | 0.06 |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | - |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn | - |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn | 0.95 |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn | 0.27 |
| 10 | Vivos Therapeutics | 9.87 Mn | 7.64 Mn | 3.06 Mn | -6.78 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -6.78 |
| Dec 31, 2025 | -5.92 |
| Sep 30, 2025 | 3.44 |
| Jun 30, 2025 | 1.73 |
| Dec 31, 2021 | 0.05 |
| Sep 30, 2021 | 0.04 |
| Jun 30, 2021 | 0.03 |
| Mar 31, 2021 | 0.09 |
| Dec 31, 2020 | 0.08 |
| Dec 31, 2019 | -1.26 |